Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: axial spondyloarthritis

Certolizumab Pegol Usage Compatible with Breastfeeding

Michele B. Kaufman, PharmD, BCGP  |  December 20, 2016

In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…

Filed under:Drug Updates Tagged with:breast milkbreastfeedingCertolizumab Pegolinfantspregnancy

Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016

Thomas R. Collins  |  September 12, 2016

LONDON—Results from the extension phase of a Phase 3 trial for the IL-17A inhibitor ixekizumab in psoriatic arthritis (PsA) show that patients started on placebo, adalimumab and ixekizumab continued to show improvements in arthritis, dactylitis and ethesitis, said Philip Mease, MD, a rheumatologist at Swedish Medical Center University of Washington in Seattle.1 Dr. Mease presented the…

Filed under:ConditionsDrug UpdatesOther Rheumatic ConditionsPsoriatic ArthritisResearch Rheum Tagged with:adalimumabDisease-modifying antirheumatic drugs (DMARDs)EULAREuropean League Against RheumatismixekizumabPsoriatic ArthritisResearchsecukinumabTreatment

Sexual Dimorphism Found in Immunologic Profiles of Patients with Ankylosing Spondylosis

Kathy Holliman  |  September 8, 2016

A study that found distinct sexual dimorphism in the immunologic profiles of patients with ankylosing spondylosis (AS) suggests that sex is an important variable to address in future research and may eventually lead to more effective sex-specific therapy for patients with the disease. The research, published in the March 2016 issue of Arthritis & Rheumatology,…

Filed under:Axial SpondyloarthritisConditionsResearch Rheum Tagged with:Ankylosing Spondylitisankylosing spondylosisImmunologypatient careResearchrheumatologysexual dimorphism

How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

Joerg Ermann, MD  |  July 13, 2016

The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…

Filed under:Axial SpondyloarthritisConditionsOther Rheumatic Conditions Tagged with:Ankylosing SpondylitisHLA-B27

Rheumatology Drug Updates: Biosimilars Receive Positive News & More

Michele B. Kaufman, PharmD, BCGP  |  April 13, 2016

On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 On Jan. 16, 2016, EMA granted marketing authorization in the European Union for Benepali to be used to treat rheumatoid arthritis (RA), psoriatic…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:adalimumabApprovalsapremilastBiologicsBiosimilarsdrugEnbreletanerceptFDAHumiraResearchrheumatologySafety

Rheumatology Drug Updates: Biosimilars Seek Regulatory Approval in the U.S., Europe; Methotrexate Underused

Michele B. Kaufman, PharmD, BCGP  |  February 16, 2016

Biosimilars Receive Positive News On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 If approved, Benepali can be used to treat rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis and plaque psoriasis….

Filed under:Biologics/DMARDsDrug Updates Tagged with:ApprovalsBiosimilarsdrugFDAIbuprofenMethotrexatepregabalinRheumatoid arthritisrheumatologySafetysarilumab

Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 3, 2016

An etanercept biosimilar referencing Enbrel and designed to treat multiple autoimmune diseases has been approved for the European market. Also, an application for subcutaneous brodalumab to treat plaque psoriasis has been submitted to the FDA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsbrodalumabetanerceptEuropean UnionFDAFood and Drug Administration

Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.

Michele B. Kaufman, PharmD, BCGP  |  January 6, 2016

In Europe, an etanercept biosimilar is getting closer to being approved to treat RA and more, and in the U.S., an application for an adalimumab biosimilar has been submitted for FDA approval. Also, an analysis of methotrexate use in the U.S. shows that therapy may actually be underused for RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:axial spondyloarthritis (SpA)BiosimilarsEuropean Medicines AgencyMethotrexateplaque psoriasisPsoriatic ArthritisRheumatoid Arthritis (RA)

Dr. St.Clair Reflects on Progress in Rheumatology

E. William St.Clair, MD  |  November 17, 2015

As a practicing rheumatologist, I have experienced the increasing payer and government involvement shaping our evolving healthcare system. New payment models, changes in health insurance coverage, the federal mandate for the adoption of electronic health records and the implementation of ICD-10 are recent changes that have rocked our world. Our patients are also paying the…

Filed under:President's PerspectiveResearch RheumWorkforce Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)GuidelinesPractice ManagementprogressResearchtransformation

Rheumatologists Share Research, Successes at Annual Investigators’ Meeting

From the College  |  October 14, 2015

“Each project adds new knowledge that brings us a little closer to the cure,” Joan Bathon, MD, of Columbia University Medical Center, says of the Rheumatology Research Foundation’s 8th Annual Investigators’ Meeting in San Diego. Dr. Bathon was one of more than 30 investigators who presented the latest progress on research funded by the Foundation’s…

Filed under:Career DevelopmentConditionsEducation & TrainingFrom the CollegeMeeting ReportsProfessional TopicsResearch RheumRheumatoid Arthritis Tagged with:education and trainingRAResearchRheumatoid arthritisrheumatologistsrheumatology

  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 19
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences